Aggressive disease treatment patterns and CtDNA HRR evaluatiON in high-volume metastatiC hORmone-sensitive prostate cancer in Russian FeDeration

Trial Identifier: D133HR00059
Sponsor: AstraZeneca
Start Date: June 2025
Primary Completion Date: June 2028
Study Completion Date: June 2028
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russian Federation Arkhangelsk, Russian Federation
Russian Federation Barnaul, Russian Federation
Russian Federation Chelyabinsk, Russian Federation
Russian Federation Ekaterinburg, Russian Federation
Russian Federation Irkutsk, Russian Federation
Russian Federation Krasnoyarsk, Russian Federation
Russian Federation Moscow, Russian Federation
Russian Federation Nizhny Novgorod, Russian Federation
Russian Federation Obninsk, Russian Federation
Russian Federation Omsk, Russian Federation
Russian Federation Saint Petersburg, Russian Federation
Russian Federation Sochi, Russian Federation
Russian Federation Tomsk, Russian Federation
Russian Federation Tver, Russian Federation
Russian Federation Tyumen, Russian Federation
Russian Federation Ufa, Russian Federation